A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
=== Hippurate === The Hippurate diagnostic test is used to differentiate between Gardnerella vaginalis, Campylobacter jejuni, Listeria monocytogenes and group B streptococci using the chemical Hippurate. The Hippurate hydrolysis pathway, capable by organisms with the necessary enzymes, produces glycine as a byproduct. Using the indicator ninhydrin, which changes color in the presence of glycine, will display either a colorless product, a negative result, of a dark blue color, a positive result.
are calculated for a short time frame, and the matrices for longer periods of time are calculated by assuming mutations follow a Markov chain model. The base unit of time for the PAM matrices is the time required for 1 mutation to occur per 100 amino acids, sometimes called 'a PAM unit' or 'a PAM' of time. This is precisely the duration of mutation assumed by the PAM1 matrix. The constant
is a small change in the volume of the system, each of which are system variables. In the fictive case in which the process is idealized and infinitely slow, so as to be called quasi-static, and regarded as reversible, the heat being transferred from a source with temperature infinitesimally above the system temperature, the heat energy may be written
Sources: en.wikipedia.org
=== Societal === In a 2012 University of Amsterdam study of 120 women, the women's luteal phase (higher levels of progesterone, and increasing levels of estrogen) was correlated with a lower level of competitive behavior in gambling and math contest scenarios, while their premenstrual phase (sharply decreasing levels of progesterone, and decreasing levels of estrogen) was correlated with a higher level of competitive behavior.
=== Anti-resorptive drugs === Anti-resorptive drugs inhibit osteoclast differentiation and function, slowing down the breakdown of bone. They are usually prescribed for patients with osteoporosis/osteopenia, or cancer metastasis to bone , such as breast, prostate cancer and multiple myeloma. These drugs are also used for rare conditions like Paget's disease, osteogenesis imperfecta and fibrous dysplasia. The two main types of anti-resorptive drugs are bisphosphonate and denosumab. These drugs help to decrease the risk of bone fracture and bone pain. Because the mandible has poorer blood circulation, it is more affected by the effects of these drugs.
During the mid-19th century, attempts were made to ship agricultural products by rail. As early as 1842, the Western Railroad of Massachusetts was reported in the June 15 edition of the Boston Traveler to be experimenting with innovative freight car designs capable of carrying all types of perishable goods without spoilage. The first refrigerated boxcar entered service in June 1851, on the Northern Railroad (New York) (or NRNY, which later became part of the Rutland Railroad). This "icebox on wheels" was a limited success since it was only functional in cold weather. That same year, the Ogdensburg and Lake Champlain Railroad (O&LC) began shipping butter to Boston in purpose-built freight cars, using ice for cooling.
Sources: en.wikipedia.org
However, in the ligation of blunt-ends, which lack protruding ends for the DNA to anneal together, the process is dependent on random collision for the ends to align together before they can be ligated, and is consequently a much less efficient process. The DNA ligase from E. coli cannot ligate blunt-ended DNA except under conditions of molecular crowding, and it is therefore not normally used for ligation in the laboratory. Instead the DNA ligase from phage T4 is used as it can ligate blunt-ended DNA as well as single-stranded DNA.
=== Bibliography === Hamburg Institute for Social Research, ed. (1999). The German Army and Genocide: Crimes Against War Prisoners, Jews, and Other Civilians in the East, 1939-1944. New York: New Press. ISBN 978-1-56584-525-1. Jentz, Thomas (1996). Panzertruppen Vol. 2 The Complete Guide to the Creation & Combat Employment of Germany's Tank Force 1943-1945. Atglen, PA: Schiffer Publishing. ISBN 0-7643-0080-6. Nafziger, George. "Organizational History of Miscelleanous German Named Infantry and Panzer Grenadier, Brigades, Verbands & Divisions, 1939-1945" (PDF). Combined Arms Research Library Digital Library. US Army Combined Arms Center. Retrieved 10 July 2016. Scheibert, Horst (1987). Culver, Bruce (ed.). Panzer Grenadier Division Grossdeutschland: A Pictorial History with Text & Maps. Translated by Gisele Hockenberry. Carrollton, Texas: Squadron/Signal Publications. ISBN 0-89747-061-3. Sharpe, Michael & Davis, Brian L (2001). Grossdeutschland: Guderian's Eastern Front Elite. Compendium Publishing. ISBN 0-7110-2854-0. Solarz, Jacek (2005). Division/Korps Großdeutschland 1943-1945. Vol. I and II. Warsaw: Wydawnictwo Militaria. ISBN 83-7219-237-5. Spaeter, Helmuth (1992). The History of the Panzerkorps Großdeutschland Vol I. Winnipeg, Canada: J. J. Fedorowicz Publishing. ISBN 0-921991-12-6. Spaeter, Helmuth (1995). The History of the Panzerkorps Großdeutschland Vol II. Winnipeg, Canada: J. J. Fedorowicz Publishing. ISBN 0-921991-27-4. Spaeter, Helmuth (2000). The History of the Panzerkorps Großdeutschland Vol III. Winnipeg, Canada: J. J. Fedorowicz Publishing.
== Further reading == papuamide Ford, PW; Gustafson, KR; McKee, TC; Shigematsu, N; Maurizi, LK; Pannell, LK; Williams, DE; de Silva, ED; Lassota, P; Allen, TM; Van Soest, R; Andersen, RJ; Boyd, MR (1999). "Papuamides A-D, HIV-Inhibitory and Cytotoxic Depsipeptides from the Sponges Theonella mirabilis and Theonella swinhoei Collected in Papua New Guinea". J. Am. Chem. Soc. 121 (25): 5899–5909. Bibcode:1999JAChS.121.5899F. doi:10.1021/ja990582o. neamphamide A Oku, N; Gustafson, KR; Cartner, LK; Wilson, JA; Shigematsu, N; Hess, S; Pannell, LK; Boyd, MR; McMahon, JB (2004). "Neamphamide A. A new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge Neamphius huxleyi". J. Nat. Prod. 67 (8): 1407–11. Bibcode:2004JNAtP..67.1407O. doi:10.1021/np040003f. PMID 15332865. callipeltin A Zampella, A; D'Auria, MV; Paloma, LG; Casapullo, A; Minale, L; Debitus, C; Henin, Y (1996). "Callipeltin A, an Anti-HIV Cyclic Depsipeptide from the New Caledonian Lithistida Sponge Callipelta sp.". J. Am. Chem. Soc. 118 (26): 6202–9. Bibcode:1996JAChS.118.6202Z. doi:10.1021/ja954287p. mirabamides A-D Plaza, A; Gustchina, E; Baker, HL; Kelly, M; Bewley, CA (2007). "Mirabamides A-D. Depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion". J. Nat. Prod. 70 (11): 1753–60. Bibcode:2007JNAtP..70.1753P. doi:10.1021/np070306k. PMID 17963357.; Andjelic, CD; Planelles, V; Barrows, LR (2008). "Characterizing the Anti-HIV Activity of Papuamide A." Mar Drugs. 6 (4): 528–49. doi:10.3390/md20080027. PMC 2630844. PMID 19172193.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.